‹ Screener

Alto Neuroscience, Inc.

ANRO · Pharmaceutical Preparations · 35.1M shares · +559%/yr ↑ dilution · EDGAR filings ↗

Grade

D46

Clinical/early-stage biotech — CNS clinical, heavy burn, very cash-rich.

Strengths

Risks

Notable findings

Key metrics

Return on equity
-41.8%
Return on assets
-34.2%
ROIC
-31.3%
Debt / equity
0.1×
Current ratio
15.7×
Free cash flow
-$52M
Tangible book value
$151M
Cash & investments
$176M
Cash runway
14q

Insider transactions · last 18 months

DateInsiderTypeSharesPrice
2026-05-14Etkin AmitGift400K
2026-03-01Smith Nicholas ConradTax withheld2.8K$19.69
2026-03-01Etkin AmitTax withheld6.2K$19.69

All non-derivative Form 4 activity (SEC), newest first.

Notable events (8-K)

DateItems
2026-05-28Exec/director changefiling ↗
2026-05-13ResultsExhibitsfiling ↗
2026-05-13Exec/director changeShareholder voteExhibitsfiling ↗
2026-04-01OtherExhibitsfiling ↗
2026-03-16Material agreement3.02OtherExhibitsfiling ↗
2026-03-16ResultsExhibitsfiling ↗
2025-11-12ResultsExhibitsfiling ↗
2025-10-20Material agreement1.023.02OtherExhibitsfiling ↗

Recent filings

FormFiledPeriodAccession
8-K2026-05-282026-05-270001999480-26-000016 ↗
8-K2026-05-132026-05-130001999480-26-000011 ↗
10-Q2026-05-132026-03-310001999480-26-000012 ↗
8-K2026-05-132026-05-120001999480-26-000014 ↗
8-K2026-04-012026-04-010001104659-26-038593 ↗
10-K2026-03-162025-12-310001999480-26-000002 ↗
8-K2026-03-162026-03-160001104659-26-027953 ↗
8-K2026-03-162026-03-160001999480-26-000001 ↗
8-K2025-11-122025-11-120001999480-25-000089 ↗
10-Q2025-11-122025-09-300001999480-25-000090 ↗
8-K2025-10-202025-10-190001104659-25-100801 ↗
8-K2025-08-132025-08-120001999480-25-000075 ↗